Why the study?
Does apixaban reduce VTE recurrence, stroke, and bleeding compared to warfarin in morbidly obese patients (BMI ≥40) with AF or VTE?
Does apixaban reduce VTE recurrence, stroke, and bleeding compared to warfarin in morbidly obese patients (BMI ≥40) with AF or VTE?
In morbidly obese patients (BMI ≥40) with AF or VTE, apixaban showed comparable efficacy to warfarin for preventing recurrent VTE and stroke, with a potentially decreased risk of major bleeding.
No takes yet. Share an insight, caveat, or question.
No difference in recurrent VTE observed; leaves open whether apixaban matches warfarin efficacy in morbidly obese patients.
Choi et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: